Expression of cancer testis antigens in thymic epithelial tumors
Expression of cancer testis antigens in thymic epithelial tumors
复制标题
DOI：
10.1111/pin.13103
复制
发表时间：
2021-04-26
影响因子：
2.2
通讯作者：
Inagaki，Hiroshi
中科院分区：
文献类型：
--
作者：
Sakane，Tadashi;Murase，Takayuki;Inagaki，Hiroshi
癌睾丸抗原（CTA）在癌细胞中检测到，但在健康正常组织中检测不到，配子发生组织除外。然而，据我们所知，抗原在胸腺上皮肿瘤中的表达尚未被研究。应用免疫组化方法检测了192例胸腺上皮性肿瘤中5种CTA（法师-A、NY-ESO-1、法师-C1、SAGE和GAGE 7）的表达。CTAs在胸腺上皮性肿瘤中呈弱阳性表达。AB型胸腺瘤的B型成分、B1/B2/B3型胸腺瘤和胸腺癌在除法师-C1外的4种CTA中显示出恶性程度与阳性表达率之间的一般正相关性。在胸腺鳞状细胞癌（SqCC）中，除法师-C1外的四种抗原均显示高表达率，范围为23.1%至43.6%。在预后分析中，SAGE（P= 0.0485）和GAGE 7（P= 0.0289）阳性表达分别与B2/B3型胸腺瘤的总生存期较短相关。在胸腺SqCC中，阳性法师-A表达与肿瘤浸润淋巴细胞中程序性死亡配体水平的增加显著相关（P= 0.0181）。我们发现（i）CTA表达频繁，（ii）CTA表达与肿瘤恶性程度的一般相关性，以及（iii）对某些CTA的预后影响。
Cancer testis antigens (CTAs) are detected in cancer cells but not in healthy normal tissues, with the exception of gametogenic tissues. However, to our knowledge, expression of the antigens in thymic epithelial tumors has not been examined yet. We examined the immunohistochemical expression of five CTAs (MAGE‐A, NY‐ESO‐1, MAGE‐C1, SAGE and GAGE7) in 192 cases of thymic epithelial tumor. The CTAs were variably expressed in the thymic epithelial tumors. Type B component of type AB thymomas, type B1/B2/B3 thymomas, and thymic carcinomas showed a generally positive correlation between the malignancy grades and positive expression rates in four CTAs other than MAGE‐C1. In thymic squamous cell carcinomas (SqCCs), four antigens except for MAGE‐C1 showed high expression rates ranging from 23.1% to 43.6%. In the prognostic analysis, a positive expression of SAGE (P= 0.0485) and GAGE7 (P= 0.0289) were associated with a shorter overall survival in type B2/B3 thymomas, respectively. In thymic SqCC, a positive MAGE‐A expression was significantly associated with an increased level of programmed death ligand in tumor‐infiltrating lymphocytes (P= 0.0181). We showed (i) a frequent CTA expression, (ii) a general correlation of CTA expression with tumor malignancy grades and (iii) a prognostic impact in some of the CTAs.